Skip to main content
    RT @drdavidliew: Can you put a bit of morphine intraarticularly inside an osteoarthritic knee and make it better?

    Cute

    David Liew drdavidliew

    1 year 3 months ago
    Can you put a bit of morphine intraarticularly inside an osteoarthritic knee and make it better? Cute idea, no bingo. I get that we're chasing better symptomatic solutions, but... Don't do this. ABST1833 #ACR22 @RheumNow https://t.co/pvsGx93eoU
    RT @drdavidliew: Erosive OA:
    have we got anything disease-modifying?
    Not much right now (read: nothing)

    Denosumab 60mg

    David Liew drdavidliew

    1 year 3 months ago
    Erosive OA: have we got anything disease-modifying? Not much right now (read: nothing) Denosumab 60mg q3mo for bone remodelling? radiographic change, erosive jt development: real improvement pain, function: zip at 48w, some at 96w? Def worth more study! ABSTL05 #ACR22 @RheumNow https://t.co/Yo9u5BlYYJ
    RT @DrTrishHarkins: PAN relapse risk ⬆️ in:
    👉severe GI involvement
    🧓>65y/o
    👉skin necrotic lesions

    PAN

    Patricia Harkins DrTrishHarkins

    1 year 3 months ago
    PAN relapse risk ⬆️ in: 👉severe GI involvement 🧓>65y/o 👉skin necrotic lesions PAN ⬆️ mortality wt: 👉AKI 🧓>65y/o 👉necrotic purpura 👉secondary PAN Abst#2232 @RheumNow #ACR22
    RT @AkhilSoodMD: Abstr #2196- COVID-19 outcomes in IMID dx in large US Hospital
    vs Pre-Omicron
    - ↑ COVID + rate (21.9

    Akhil Sood MD AkhilSoodMD

    1 year 3 months ago
    Abstr #2196- COVID-19 outcomes in IMID dx in large US Hospital vs Pre-Omicron - ↑ COVID + rate (21.9% vs 7.9%) - ↓ hospitalized (0.8% vs 3%) & death (1.8% vs 4.5%) - Hospitalization & death > gen pop both pd. -Age & comorbidities assoc w worse outcomes @RheumNow #ACR22
    RT @drdavidliew: Biosimilar multi-switching in RA: is it an issue?

    Switching back & forth between originator &

    David Liew drdavidliew

    1 year 3 months ago
    Biosimilar multi-switching in RA: is it an issue? Switching back & forth between originator & biosimilar should create ideal conditions for immunogenicity or anti-drug Ab This study: multi-switching vs no switching No issues at all Switch away in RA! ABST1589 #ACR22 @RheumNow https://t.co/pGBF2BHp7y
    We want to see how you are taking in #ACR22! Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR

    Dr. John Cush RheumNow

    1 year 3 months ago
    We want to see how you are taking in #ACR22! Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/ygfYol5Z3f
    The last day was jammed with important reports and research including the late breaking abstracts.   
    Curcumin, the active constituent of turmeric extract, has increasingly been promoted as a potential rheumatoid arthritis therapy, but data presented at ACR22 suggests that even in ideal situations, it is unable to do any better than placebo in replacing conventional RA therapies.
    A few things we know about opioids: use is common; it’s not efficacious in the treatment of spondyloarthritis; and, there is an opioid epidemic and its users are stigmatized. Abstract 0402 is a retrospective study that looked at patients with psoriatic arthritis or ankylosing spondylitis in the FORWARD databank. It sheds new light and leaves us with some food for thought
    RT @drdavidliew: @rheumecraig @RheumNow Absolutely. In this #ACR22 study, they did exclude anyone with deranged LFTs fro

    David Liew drdavidliew

    1 year 3 months ago
    @rheumecraig @RheumNow Absolutely. In this #ACR22 study, they did exclude anyone with deranged LFTs from this study and yet still two people in the turmeric arm got LFT derangement (vs zero in placebo). Sadly I don't think the turmeric salespeople are watching the LFTs.
    RT @AkhilSoodMD: Abstr #2191 studies impact of maternal SLE on outcomes of children
    Maternal SLE assoc w/ ↑ odds of
    -

    Akhil Sood MD AkhilSoodMD

    1 year 3 months ago
    Abstr #2191 studies impact of maternal SLE on outcomes of children Maternal SLE assoc w/ ↑ odds of - SLE of children (HR 98.48, 95%CI:63.39-152.98) - other AutoImm dx (HR 1.26, 1.02-1.57) (Hashimoto, JRA, IBD) - Neurodev dx (1.35, 95%CI:1.15-1.57) (ADHD) @RheumNow #ACR22
    RT @uptoTate: UPA tx in prior TNFi tx PsA pts demonstrated consistent efficacy compared to the overall population in SEL

    Dr. Rachel Tate uptoTate

    1 year 3 months ago
    UPA tx in prior TNFi tx PsA pts demonstrated consistent efficacy compared to the overall population in SELECT-PsA 2, regardless of number of prior anti-TNF therapies. Abs 2146 #ACR22 @RheumNow https://t.co/xnN4nvZ934 https://t.co/3S6ZzPvqVe
    RT @RHEUMarampa: How to adjust for GC correction when dose >/= 7.5mg/d using FRAX?
    Calculate FRAX then
    🦴For MOF r

    sheila RHEUMarampa

    1 year 3 months ago
    How to adjust for GC correction when dose >/= 7.5mg/d using FRAX? Calculate FRAX then 🦴For MOF risk multiply by 1.15 🦴HF risk multiply by 1.2 = adjusted risk (%) (Adjustment of FRAX accdg to GC dose from Kanis et al., OI 2011) #ACR22 @RheumNow @Rheumarhyme @PhRheumaJr https://t.co/qap1fFhF0h
    One of the enduring legacies of ACR 2022 for me will be the emphasis on polymyalgia rheumatica (PMR). Despite being highly inflammatory and relatively common, a remarkable paucity of trials have been run in this space. Read on for a quick PMR-roundup from the meeting!